NEU 2.99% $20.10 neuren pharmaceuticals limited

Share Price, page-56

  1. 574 Posts.
    lightbulb Created with Sketch. 299
    Seekingalpha:

    • ACADIA Pharmaceuticals (ACAD +8.9%) has recorded the biggest intraday gain since March after Guggenheim raised its rating on the biotech to Buy from Neutral.
    • The analyst Yatin Sunejaa has a favorable view on the company’s upcoming Phase 3 topline data read for its Rett syndrome candidate trofinetide scheduled for Q4 2021.
    • “Given the limited investor interest in this program, we like the risk-reward heading into the readout,” Sunejaa wrote with the price target of $23 per share of Acadia (NASDAQ:ACAD), implying a premium of ~28.1% to the last close.
    • In addition to the Phase II study, “one more successful trial will be sufficient to file an NDA in 2022,” the firm noted, citing the company management.
    • In March 2020, Acadia (ACAD) announced that the FDA granted the Rare Pediatric Disease designation to trofinetide in the treatment of Rett syndrome.

    Now +12%
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.10
Change
-0.620(2.99%)
Mkt cap ! $2.569B
Open High Low Value Volume
$20.41 $20.45 $19.92 $5.947M 296.0K

Buyers (Bids)

No. Vol. Price($)
1 999 $20.10
 

Sellers (Offers)

Price($) Vol. No.
$20.19 10 1
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.